Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
ALK tyrosine kinase inhibitor

Zykadia (ceritinib)

An approved treatment for ALK-Positive Lung Cancer.

FDA Approved (2014)by Novartis
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2014

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Ceritinib wherever you encounter it, plus the key facts at a glance.

Generic name
Ceritinib
Brand name
Zykadia
Development code
LDK378
Drug class
ALK tyrosine kinase inhibitor
Manufacturer
Novartis
How it's taken
Oral tablets, once a day with food

Zykadia (ceritinib) is a pill taken once a day with food for adults with non-small cell lung cancer that has spread (metastatic).

  • It is for people whose tumor tests ALK-positive on an FDA-approved test[1].
  • The FDA first approved it on April 29, 2014 under accelerated approval for ALK-positive lung cancer that had grown on crizotinib (Xalkori) or for people who could not tolerate crizotinib[2].
  • On May 26, 2017 the FDA widened the approval to metastatic ALK-positive lung cancer whether or not crizotinib came first, based on the ASCEND-4 trial[3].
  • The label dose is 450mg, taken as 3 tablets of 150mg, once a day with food[1].
  • In ASCEND-4, in people who had not had treatment for metastatic disease, the cancer took a median 16.6 months to grow on ceritinib against 8.1 months on platinum chemotherapy[1].
  • The label says its safety and effectiveness in children have not been established[1].
Follow Zykadia by email

We'll email you when Zykadia's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Ceritinib fits

Zykadia (ceritinib) is a once-daily ALK inhibitor, taken with food, approved for adults with metastatic ALK-positive non-small cell lung cancer found by an FDA-approved test[1].

  • Crizotinib (Xalkori), alectinib (Alecensa), brigatinib (Alunbrig) and lorlatinib (Lorbrena) are also FDA approved for metastatic ALK-positive lung cancer[8][9][10][11].
  • Ensartinib (Ensacove) is approved for people who have not taken an ALK inhibitor[12].
  • Neladalkib (Nelkarmi) is approved under accelerated approval for locally advanced or metastatic disease already treated with alectinib as the only ALK inhibitor. That approval also covers disease already treated with 2 or more ALK inhibitors plus platinum chemotherapy[13].
  • Ceritinib was tested against platinum chemotherapy in ASCEND-4 and, in ASCEND-1, in people whose cancer had grown on crizotinib or who could not tolerate it[1].
  • The newer drugs alectinib, brigatinib, lorlatinib and ensartinib were each tested against crizotinib rather than ceritinib[9][10][11][12].
  • No label reports a trial comparing ceritinib directly with another ALK inhibitor[1].
  • Anyone curious about ceritinib can ask their oncologist how its warnings for blood sugar, the liver and the pancreas would be watched alongside their other health conditions.

How Ceritinib works

In ALK-positive lung cancer, a piece of the ALK gene joins another gene, such as one called EML4. The fused gene makes an ALK protein that stays switched on and keeps telling cancer cells to grow[1][8]. Ceritinib blocks that ALK protein and the signal it sends to a protein called STAT3, and it stopped ALK-dependent cancer cells from growing in laboratory and animal tests[1].

The label reports that it slowed EML4-ALK lung tumors in mice that had become resistant to crizotinib, at drug levels people reach[1]. Ceritinib also blocks IGF-1R, the insulin receptor and ROS1, though the label says it is most active against ALK[1].

Side effects and safety

What patients report

Zykadia has no boxed warning, and the label lists no contraindications[1]. The label's warnings are stomach and bowel side effects, liver injury, lung inflammation and a heart rhythm change called QT prolongation. The others are high blood sugar, a slow heart rate, pancreatitis and harm to an unborn baby[1].

Stomach and bowel: At the older 750mg dose taken on an empty stomach, 95% of 925 people had diarrhea, nausea, vomiting or belly pain. These side effects were severe in 14%[1]. In the ASCEND-8 dose study, these side effects occurred in 79% of 108 people taking the current 450mg dose with food. Most were mild (53%) or moderate (24%). There was 1 case of grade 3 diarrhea and 1 of grade 3 vomiting[1]. In that group, diarrhea occurred in 59%, nausea in 43% and vomiting in 38%[1].

Liver: Across 925 people, the liver enzyme ALT rose above 5 times the normal limit in 28% and AST in 16%. About 1% stopped Zykadia for good because of liver injury[1]. Liver blood tests are checked monthly and as needed, more often if enzymes rise[1].

Lungs: Interstitial lung disease, also called pneumonitis, is swelling and scarring of lung tissue. It occurred in 2.4% of the 925 people, was grade 3 or 4 in 1.3% and fatal in 0.2%. Zykadia is stopped for good if treatment-related lung disease is found[1].

Heart rhythm: The QT interval on an ECG rose by more than 60 milliseconds in 6% of 919 people. About 1.3% of people on the 750mg fasted dose had a QT interval above 500 milliseconds[1]. The label says to avoid Zykadia when possible in people born with long QT syndrome. It also says to check ECGs and blood salts in people with heart failure, slow heart rhythms, salt imbalances or medicines that prolong the QT interval[1].

Blood sugar: Severe high blood sugar (grade 3 or 4) occurred in 13% of the 925 people. Fasting blood sugar is checked before starting and from time to time after[1]. In ASCEND-4, people with uncontrolled diabetes could not join[1].

Slow heart rate: A new heart rate under 50 beats a minute was found in 1.1% of the 925 people[1]. Heart rate and blood pressure are checked regularly. The label advises avoiding other medicines that slow the heart as far as possible. Examples are beta-blockers, non-dihydropyridine calcium channel blockers, clonidine and digoxin[1].

Pancreas: Pancreatitis occurred in less than 1% of people, including 1 death. Severe rises in the pancreas enzymes lipase (14%) and amylase (7%) were more common[1]. Lipase and amylase are checked before starting and from time to time after[1].

Pregnancy: Zykadia can harm an unborn baby. The label calls for effective birth control during treatment and for 6 months after. It also calls for male patients with partners who could become pregnant to use condoms during treatment and for 3 months after[1]. Breastfeeding is not advised during treatment and for 2 weeks after[1].

Most common: At 450mg with food, the side effects seen in 25% or more were diarrhea, nausea, belly pain, vomiting and tiredness[1]. In ASCEND-4, at the older 750mg fasted dose, serious side effects occurred in 38%. In that trial, 66% needed a lower dose and 12% stopped Zykadia for good because of side effects[1].

Lab changes: In ASCEND-4, ALT rose in 91% (severe in 34%) and the liver enzyme GGT in 84%. Creatinine, a kidney blood test, rose in 77% and blood sugar in 53%[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Ceritinib

The label dose is 450mg by mouth once a day with food[1]. Zykadia tablets are 150mg, which means 3 tablets for the full dose[1]. The label also describes 150mg capsules, which Drugs@FDA lists as discontinued[1][6].

Missed or vomited doses: A missed dose is taken unless the next dose is due within 12 hours, and no extra dose is taken after vomiting[1].

Lower doses: For side effects, the doctor may pause Zykadia or lower the dose to 300mg and then 150mg once a day with food. Zykadia is stopped for good in people who cannot tolerate 150mg[1]. For severe liver impairment (Child-Pugh C), the dose is cut by about a third, rounded to the nearest 150mg[1].

Tests during treatment: Liver tests are done monthly, and heart rate and blood pressure are checked regularly. Fasting blood sugar, lipase and amylase are checked before starting and from time to time after[1]. A pregnancy test is done before starting for anyone who could become pregnant[1].

Other medicines: The label says to avoid strong CYP3A inhibitors, which raise ceritinib levels. If one cannot be avoided, the label says to cut the Zykadia dose by about a third[1]. Grapefruit and grapefruit juice are not to be consumed, and strong CYP3A inducers are avoided because they lower ceritinib levels[1]. Ceritinib raises the levels of midazolam and warfarin, and the label calls for more frequent INR blood tests if warfarin cannot be avoided[1]. The label also advises avoiding, when possible, medicines that prolong the QT interval or slow the heart rate[1].

Availability and cost

No generic available

Only available as the brand-name product.

Help paying for Zykadia

With private insurance, the drugmaker's copay card can lower what you pay for Zykadia. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 4 charity funds for ALK-Positive Lung Cancer were open on November 18, 2026. People on Medicare may still qualify for the drugmaker's free medicine program. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Zykadia (Ceritinib)
Some details not published
Novartis Oncology Universal Co-pay Program
  • Copay help

    Novartis Oncology Universal Co-pay Program: lists Zykadia in its medication selector. Under the general terms, privately insured patients are responsible for up to the first $25, with the specific offer varying by brand, and a combined annual limit of $15,000 per calendar year. Not for anyone enrolled in Medicare, Medicaid, TRICARE, VA, DoD or other federal or state programs, and not valid for Massachusetts patients. California patients must meet additional eligibility criteria, which the site does not spell out. Call 1-877-577-7756.

    For: private insurance · source
  • Free medicine program

    Novartis Patient Assistance Foundation (NPAF): provides Novartis medicines free of cost to eligible patients who are uninsured or have government insurance, live in the US or a US territory, are treated by a licensed US provider as outpatients and meet income guidelines. Zykadia (ceritinib) is on its list of supported medicines. Call 1-800-277-2254.

    For: no insurance, Medicare, Medicaid · source

Good to know: Partial: the co-pay site gives only general terms for all Novartis oncology brands ('specific offer varies by brand') and lists Zykadia as capsules, which Drugs@FDA marks as discontinued; no Zykadia-specific co-pay terms were found. NPAF does not publish its income limits, and neither page lists hours. Novartis's September 2024 Financial Support sheet also lists a Zykadia co-pay program at 1-844-638-7222. zykadia.com redirected to the Novartis product list on November 18, 2026, and Novartis's Zykadia product page links only to the label and the NPAF enrollment page. The Novartis co-pay page states 2 different yearly limits, $30,000 and a combined $15,000; this record shows the $15,000 figure until Novartis confirms which applies to Zykadia.

Checked on the drugmaker's official pages on November 18, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for ALK-Positive Lung Cancer

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 18, 2026.

Every program and charity fund for ALK-Positive Lung Cancer →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Clinical trial results

ASCEND-4 (NCT01828099) was a randomized, open-label Phase 3 trial in 376 people with ALK-positive lung cancer who had not had treatment for metastatic disease. It compared ceritinib 750mg on an empty stomach with pemetrexed plus cisplatin or carboplatin chemotherapy followed by pemetrexed[1][7]. Results judged by blinded independent reviewers[1]:

  • Median time before the cancer grew or the person died (progression-free survival) was 16.6 months on ceritinib and 8.1 months on chemotherapy
  • Tumors shrank in 73% on ceritinib and 27% on chemotherapy
  • Median response lasted 23.9 months on ceritinib and 11.1 months on chemotherapy
  • Overall survival showed no significant difference at a planned interim look, done at 42% of the deaths needed for the final analysis

Brain: In people with measurable brain metastases, brain tumors shrank in 57% of 28 on ceritinib and 22% of 27 on chemotherapy[1].

After crizotinib: ASCEND-1 (NCT01283516) gave ceritinib 750mg on an empty stomach to 163 people whose ALK-positive lung cancer had grown on crizotinib or who could not tolerate it[1]. Tumors shrank in 44% by independent review and 55% by the study doctors, and the median response lasted 7.1 months by independent review[1].

Dose study: ASCEND-8 compared 450mg with food against 750mg on an empty stomach in 218 people. The label reports similar drug levels with fewer stomach and bowel side effects at 450mg with food[1].

Not compared: The Zykadia label reports no trial comparing ceritinib directly with crizotinib or any other ALK inhibitor[1].

Development history

Novartis developed ceritinib under the code LDK378[7]. The FDA granted accelerated approval on April 29, 2014 for ALK-positive lung cancer that had grown on crizotinib or in people who could not tolerate it. The approval was based on how many tumors shrank and how long that lasted[2]. On May 26, 2017 the FDA approved a broader use for metastatic ALK-positive lung cancer based on ASCEND-4.

The FDA said the trial verified the clinical benefit required by the 2014 accelerated approval[3]. The same letter notes an Orphan Drug designation for this use[3]. On December 21, 2017 the FDA changed the dose from 750mg on an empty stomach to 450mg with food[4][6]. The FDA approved the 150mg tablet on March 18, 2019 for the same uses as the capsules[5].

Ask anything about Ceritinib
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore ALK-Positive Lung Cancer trials

Other ALK-Positive Lung Cancer treatments

Common questions about Ceritinib

▸What is Ceritinib (Zykadia)?

Zykadia (ceritinib) is a pill taken once a day with food for adults with non-small cell lung cancer that has spread (metastatic). It is for people whose tumor tests ALK-positive on an FDA-approved test[1]. The FDA first approved it on April 29, 2014 under accelerated approval for ALK-positive lung cancer that had grown on crizotinib (Xalkori) or for people who could not tolerate crizotinib[2]. On May 26, 2017 the FDA widened the approval to metastatic ALK-positive lung cancer whether or not crizotinib came first, based on the ASCEND-4 trial[3]. The label dose is 450mg, taken as 3 tablets of 150mg, once a day with food[1]. In ASCEND-4, in people who had not had treatment for metastatic disease, the cancer took a median 16.6 months to grow on ceritinib against 8.1 months on platinum chemotherapy[1]. The label says its safety and effectiveness in children have not been established[1].

▸How does Ceritinib work?

In ALK-positive lung cancer, a piece of the ALK gene joins another gene, such as one called EML4. The fused gene makes an ALK protein that stays switched on and keeps telling cancer cells to grow[1][8]. Ceritinib blocks that ALK protein and the signal it sends to a protein called STAT3, and it stopped ALK-dependent cancer cells from growing in laboratory and animal tests[1]. The label reports that it slowed EML4-ALK lung tumors in mice that had become resistant to crizotinib, at drug levels people reach[1]. Ceritinib also blocks IGF-1R, the insulin receptor and ROS1, though the label says it is most active against ALK[1].

▸What are the side effects of Ceritinib?

Zykadia has no boxed warning, and the label lists no contraindications[1]. The label's warnings are stomach and bowel side effects, liver injury, lung inflammation and a heart rhythm change called QT prolongation. The others are high blood sugar, a slow heart rate, pancreatitis and harm to an unborn baby[1].

Stomach and bowel: At the older 750mg dose taken on an empty stomach, 95% of 925 people had diarrhea, nausea, vomiting or belly pain. These side effects were severe in 14%[1]. In the ASCEND-8 dose study, these side effects occurred in 79% of 108 people taking the current 450mg dose with food. Most were mild (53%) or moderate (24%). There was 1 case of grade 3 diarrhea and 1 of grade 3 vomiting[1]. In that group, diarrhea occurred in 59%, nausea in 43% and vomiting in 38%[1].

Liver: Across 925 people, the liver enzyme ALT rose above 5 times the normal limit in 28% and AST in 16%. About 1% stopped Zykadia for good because of liver injury[1]. Liver blood tests are checked monthly and as needed, more often if enzymes rise[1].

Lungs: Interstitial lung disease, also called pneumonitis, is swelling and scarring of lung tissue. It occurred in 2.4% of the 925 people, was grade 3 or 4 in 1.3% and fatal in 0.2%. Zykadia is stopped for good if treatment-related lung disease is found[1].

Heart rhythm: The QT interval on an ECG rose by more than 60 milliseconds in 6% of 919 people. About 1.3% of people on the 750mg fasted dose had a QT interval above 500 milliseconds[1]. The label says to avoid Zykadia when possible in people born with long QT syndrome. It also says to check ECGs and blood salts in people with heart failure, slow heart rhythms, salt imbalances or medicines that prolong the QT interval[1].

Blood sugar: Severe high blood sugar (grade 3 or 4) occurred in 13% of the 925 people. Fasting blood sugar is checked before starting and from time to time after[1]. In ASCEND-4, people with uncontrolled diabetes could not join[1].

Slow heart rate: A new heart rate under 50 beats a minute was found in 1.1% of the 925 people[1]. Heart rate and blood pressure are checked regularly. The label advises avoiding other medicines that slow the heart as far as possible. Examples are beta-blockers, non-dihydropyridine calcium channel blockers, clonidine and digoxin[1].

Pancreas: Pancreatitis occurred in less than 1% of people, including 1 death. Severe rises in the pancreas enzymes lipase (14%) and amylase (7%) were more common[1]. Lipase and amylase are checked before starting and from time to time after[1].

Pregnancy: Zykadia can harm an unborn baby. The label calls for effective birth control during treatment and for 6 months after. It also calls for male patients with partners who could become pregnant to use condoms during treatment and for 3 months after[1]. Breastfeeding is not advised during treatment and for 2 weeks after[1].

Most common: At 450mg with food, the side effects seen in 25% or more were diarrhea, nausea, belly pain, vomiting and tiredness[1]. In ASCEND-4, at the older 750mg fasted dose, serious side effects occurred in 38%. In that trial, 66% needed a lower dose and 12% stopped Zykadia for good because of side effects[1].

Lab changes: In ASCEND-4, ALT rose in 91% (severe in 34%) and the liver enzyme GGT in 84%. Creatinine, a kidney blood test, rose in 77% and blood sugar in 53%[1].

▸How is Ceritinib taken?

The label dose is 450mg by mouth once a day with food[1]. Zykadia tablets are 150mg, which means 3 tablets for the full dose[1]. The label also describes 150mg capsules, which Drugs@FDA lists as discontinued[1][6].

Missed or vomited doses: A missed dose is taken unless the next dose is due within 12 hours, and no extra dose is taken after vomiting[1].

Lower doses: For side effects, the doctor may pause Zykadia or lower the dose to 300mg and then 150mg once a day with food. Zykadia is stopped for good in people who cannot tolerate 150mg[1]. For severe liver impairment (Child-Pugh C), the dose is cut by about a third, rounded to the nearest 150mg[1].

Tests during treatment: Liver tests are done monthly, and heart rate and blood pressure are checked regularly. Fasting blood sugar, lipase and amylase are checked before starting and from time to time after[1]. A pregnancy test is done before starting for anyone who could become pregnant[1].

Other medicines: The label says to avoid strong CYP3A inhibitors, which raise ceritinib levels. If one cannot be avoided, the label says to cut the Zykadia dose by about a third[1]. Grapefruit and grapefruit juice are not to be consumed, and strong CYP3A inducers are avoided because they lower ceritinib levels[1]. Ceritinib raises the levels of midazolam and warfarin, and the label calls for more frequent INR blood tests if warfarin cannot be avoided[1]. The label also advises avoiding, when possible, medicines that prolong the QT interval or slow the heart rate[1].

▸Is Ceritinib FDA approved?

Yes, Ceritinib (Zykadia) is FDA approved (2014) for the treatment of ALK-Positive Lung Cancer.

▸Should Zykadia be taken with food?

Yes. The label dose is 450mg once a day with food.

Why: In the ASCEND-8 study, 450mg with food gave drug levels similar to the older 750mg empty-stomach dose, with fewer stomach and bowel side effects.

Tablets: The dose is 3 tablets of 150mg.

Missed dose: A missed dose is taken unless the next dose is due within 12 hours.

Grapefruit: The label says not to consume grapefruit or grapefruit juice.

More: ALK-positive lung cancer treatments compared

Source: Zykadia prescribing information, DailyMed, October 2026

▸What are the side effects of ceritinib?

Stomach and bowel side effects are the most common, in 79% of people taking 450mg with food in the ASCEND-8 study, and most were mild or moderate.

Most common: Diarrhea, nausea, belly pain, vomiting and tiredness.

Warnings: Liver injury, lung inflammation, QT prolongation on an ECG, high blood sugar, a slow heart rate, pancreatitis and harm to an unborn baby.

Liver: ALT rose above 5 times the normal limit in 28% of 925 people across studies.

Blood sugar: Severe high blood sugar occurred in 13% of 925 people.

Monitoring: Liver tests monthly, plus fasting blood sugar, lipase and amylase before starting and from time to time after.

Source: Zykadia prescribing information, DailyMed, October 2026

▸Does ceritinib work after crizotinib?

In the ASCEND-1 study of 163 people whose cancer had grown on crizotinib or who could not tolerate it, tumors shrank in 44% by independent review.

How long: The median response lasted 7.1 months by independent review.

Study doctors: They judged that tumors shrank in 55%.

Design: Everyone took ceritinib, with no comparison group, at the older 750mg empty-stomach dose.

Approval: ASCEND-1 was the basis for the FDA's 2014 accelerated approval.

Source: Zykadia prescribing information, DailyMed, October 2026; FDA approval letter, April 29, 2014

▸What did the ASCEND-4 trial of Zykadia show?

In 376 people with ALK-positive lung cancer and no earlier treatment for metastatic disease, the cancer took a median 16.6 months to grow on ceritinib against 8.1 months on chemotherapy.

Response: Tumors shrank in 73% on ceritinib and 27% on chemotherapy.

Brain: Brain metastases shrank in 57% of 28 people on ceritinib and 22% of 27 on chemotherapy.

Survival: An early look found no significant difference in overall survival.

Dose: The trial used 750mg on an empty stomach, before the label moved to 450mg with food.

Source: Zykadia prescribing information, DailyMed, October 2026

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. U.S. National Library of Medicine, DailyMed · 2026-10. ZYKADIA (CERITINIB) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e
  2. U.S. Food and Drug Administration · 2014-04-29. NDA 205755 ACCELERATED APPROVAL. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205755Orig1s000ltr.pdf
  3. U.S. Food and Drug Administration · 2017-05-26. NDA 205755/S-09 SUPPLEMENT APPROVAL. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/205755Orig1s009ltr.pdf
  4. U.S. Food and Drug Administration · 2017-12-21. NDA 205755/S-010 SUPPLEMENT APPROVAL. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/205755Orig1s010ltr.pdf
  5. U.S. Food and Drug Administration · 2019-03-18. NDA 211225 NDA APPROVAL. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211225Orig1s000ltr.pdf
  6. U.S. Food and Drug Administration · 2026-11-18. Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205755
  7. ClinicalTrials.gov · 2026-11-18. LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer. https://clinicaltrials.gov/study/NCT01828099
  8. U.S. National Library of Medicine, DailyMed · 2026-11. XALKORI (CRIZOTINIB) CAPSULE XALKORI (CRIZOTINIB) CAPSULE, COATED PELLETS [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7
  9. U.S. National Library of Medicine, DailyMed · 2026-08. ALECENSA (ALECTINIB HYDROCHLORIDE) CAPSULE [GENENTECH, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb
  10. U.S. National Library of Medicine, DailyMed · 2026-01. ALUNBRIG (BRIGATINIB) TABLET, FILM COATED ALUNBRIG (BRIGATINIB) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db
  11. U.S. National Library of Medicine, DailyMed · 2026-06. LORBRENA (LORLATINIB) TABLET, FILM COATED [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d
  12. U.S. National Library of Medicine, DailyMed · 2026-02. ENSACOVE (ENSARTINIB) CAPSULE [XCOVERY HOLDINGS, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e
  13. Nuvalent, Inc. · 2026-11. NELKARMI (neladalkib) tablets, for oral use: Full Prescribing Information. https://nuvalent.com/pdfs/nelkarmi-full-prescribing-information.pdf

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Zykadia by email

We'll email you when Zykadia's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site